<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02780700</url>
  </required_header>
  <id_info>
    <org_study_id>1199.251</org_study_id>
    <nct_id>NCT02780700</nct_id>
  </id_info>
  <brief_title>Nintedanib Alone or in Combination With Capecitabine in Refractory Metastatic Colorectal Cancer [LUME-Colon 2]</brief_title>
  <official_title>LUME-Colon 2: An Open-label Randomized Phase II Study to Assess the Efficacy and Safety of Nintedanib Alone or in Combination With Capecitabine for Patients With Refractory Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective of this Phase II study is to assess the efficacy and safety of nintedanib alone&#xD;
      or in combination with capecitabine for patients with refractory metastatic colorectal cancer&#xD;
      (mCRC) after failure of at least 2 lines of standard treatment&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Substance discontinued&#xD;
  </why_stopped>
  <start_date>July 5, 2016</start_date>
  <completion_date type="Actual">September 9, 2016</completion_date>
  <primary_completion_date type="Actual">September 9, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Data collected up to cut-off date 09 Sep 2016, Up to 02 months</time_frame>
    <description>PFS is defined as the time from randomization until objective tumor progression or death.&#xD;
Since only one patient was enrolled prior to termination of the trial, no data summarization or analysis was carried out.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Data collected up to cut-off date 09 Sep 2016, Up to 02 months</time_frame>
    <description>Overall survival is defined as the time from randomization until death from any cause.&#xD;
Since only one patient was enrolled prior to termination of the trial, no data summarization or analysis was carried out.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>tumor response was to be assessed by imaging according to RECIST (version 1.1) every 6 weeks.</time_frame>
    <description>ORR is defined as complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.&#xD;
Since only one patient was enrolled prior to termination of the trial, no data summarization or analysis was carried out.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control (DC)</measure>
    <time_frame>Data collected up to cut-off date 09 Sep 2016, Up to 02 months</time_frame>
    <description>Disease control is defined as CR or PR or Stable disease (SD) per RECIST version 1.1.&#xD;
Since only one patient was enrolled prior to termination of the trial, no data summarization or analysis was carried out.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Grade 3 or Worse Adverse Events</measure>
    <time_frame>Data collected up to cut-off date 09 Sep 2016, Up to 02 months</time_frame>
    <description>Percentage of patients with grade 3 or worse adverse events.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Colorectal Neoplasms</condition>
  <arm_group>
    <arm_group_label>Nintedanib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Nintedanib plus capecitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nintedanib</intervention_name>
    <arm_group_label>Nintedanib</arm_group_label>
    <arm_group_label>Nintedanib plus capecitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <arm_group_label>Nintedanib plus capecitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed colorectal adenocarcinoma&#xD;
&#xD;
          -  Metastatic or locally advanced disease not amenable to curative surgery and/or&#xD;
             radiotherapy&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status &lt;= 1&#xD;
&#xD;
          -  At least one measurable lesion according to RECIST 1.1&#xD;
&#xD;
          -  Previously treated with all of the following: fluoropyrimidine, (e.g. 5-fluorouracil&#xD;
             (5-FU), capecitabine or TAS-102); oxaliplatin: Patients treated with oxaliplatin in&#xD;
             adjuvant setting should have progressed within 6 months of completion of adjuvant&#xD;
             therapy or they must have been treated with oxaliplatin for metastatic disease;&#xD;
             Irinotecan; Vascular Endothelial Growth Factor (VEGF) directed treatment (e.g.&#xD;
             bevacizumab, aflibercept, ramucirumab or regorafenib); cetuximab or panitumumab for&#xD;
             patients with K-Ras wt or Ras wt tumors&#xD;
&#xD;
          -  Minimal time interval of 3 weeks between the last administration of Colorectal Cancer&#xD;
             (CRC) treatment (cytotoxics or targeted agents) and starting of trial therapy&#xD;
&#xD;
          -  Adequate liver and kidney function&#xD;
&#xD;
          -  Further inclusion criteria apply&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Prior treatment with nintedanib.&#xD;
&#xD;
          -  Any other investigational agent received within 3 weeks prior to randomization&#xD;
&#xD;
          -  Known hypersensitivity or intolerability to the trial drugs or their excipients&#xD;
&#xD;
          -  History of other malignancies in the last 5 years, in particular those that could&#xD;
             interfere with interpretation of results. Patients with adequately treated basal or&#xD;
             squamous cell skin cancer or cervix carcinoma and other early stage cancer treated&#xD;
             curatively are eligible&#xD;
&#xD;
          -  History of severe or unexpected reactions to fluoropyrimidine therapy or any of its&#xD;
             excipients&#xD;
&#xD;
          -  Known dihydropyrimidine dehydrogenase (DPD) deficiency&#xD;
&#xD;
          -  Treatment with sorivudine or its chemically related analogues, such as brivudine&#xD;
&#xD;
          -  Serious concomitant disease or medical condition affecting compliance with trial&#xD;
             requirements or which are considered relevant for the evaluation of the efficacy or&#xD;
             safety of the trial drug, such as neurologic, psychiatric, infectious disease or&#xD;
             active ulcers (gastro-intestinal tract, skin) or laboratory abnormality that may&#xD;
             increase the risk associated with trial participation or trial drug administration,&#xD;
             and in the judgment of the investigator would make the patient inappropriate for entry&#xD;
             into the trial&#xD;
&#xD;
          -  Major injuries and/or surgery or bone fracture within 4 weeks of trial inclusion&#xD;
             (signing Informed Consent), or planned surgical procedures during the trial period&#xD;
&#xD;
          -  Significant cardiovascular diseases (i.e. uncontrolled hypertension, unstable angina,&#xD;
             history of myocardial infarction within past 6 months of trial inclusion, congestive&#xD;
             heart failure &gt; New York Heart Association (NYHA) II)&#xD;
&#xD;
          -  History of severe hemorrhagic or thromboembolic event in the past 6 months (excluding&#xD;
             central venous catheter thrombosis and peripheral deep vein thrombosis). Known&#xD;
             inherited predisposition to bleeding or to thrombosis&#xD;
&#xD;
          -  Bleeding or thrombotic disorders requiring anticoagulant therapy such as warfarin, or&#xD;
             similar agents requiring therapeuticInternational normalized ratio (INR) monitoring&#xD;
             (treatment with low molecular weight heparin and/or heparin flush as needed for&#xD;
             maintenance of an indwelling intravenous device is allowed)&#xD;
&#xD;
          -  Inflammatory bowel disease and other serious medical conditions increasing the risk of&#xD;
             perforation or bleeding according to investigator's judgment&#xD;
&#xD;
          -  Gastrointestinal disorders or abnormalities that would interfere with absorption of&#xD;
             study drug&#xD;
&#xD;
          -  Patient with brain metastases that are symptomatic and/or require therapy. Patients&#xD;
             with previously treated and stable brain metastases are allowed&#xD;
&#xD;
          -  Further exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fort Wayne Medical Oncology Hematology</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
    <description>Related Info</description>
  </link>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>May 20, 2016</study_first_submitted>
  <study_first_submitted_qc>May 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2016</study_first_posted>
  <results_first_submitted>August 2, 2018</results_first_submitted>
  <results_first_submitted_qc>September 12, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 11, 2018</results_first_posted>
  <last_update_submitted>September 12, 2018</last_update_submitted>
  <last_update_submitted_qc>September 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Nintedanib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was an exploratory, phase II multi-center, non-comparative, open-label, randomized trial to assess the efficacy and safety of nintedanib alone, or in combination with capecitabine in patients with refractory metastatic colorectal cancer.</recruitment_details>
      <pre_assignment_details>Patients eligible for this study were to be randomized in a 1:1 fashion to receive either nintedanib alone or combination with capecitabine.&#xD;
One patient with combination therapy entered study, no patient with nintedanib alone entered study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Nintedanib Plus Capecitabine</title>
          <description>Patients were to be orally administered tablets of Nintedanib and 1000 mg/m2 Capecitabine twice daily.&#xD;
Nintedanib: 21 day cycles; Capecitabine: first 14 days of each 21 day cycle</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Progressive disease</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated set (TS): This will comprise all patients who are randomized and are documented to have taken at least one dose of trial medication</population>
      <group_list>
        <group group_id="B1">
          <title>Nintedanib Plus Capecitabine</title>
          <description>Patients were to be orally administered tablets of Nintedanib and 1000 mg/m2 Capecitabine twice daily.&#xD;
Nintedanib: 21 day cycles; Capecitabine: first 14 days of each 21 day cycle</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>TS</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" spread="NA">Not Applicable as only one patient was treated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>TS</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <population>TS</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <population>TS</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival (PFS)</title>
        <description>PFS is defined as the time from randomization until objective tumor progression or death.&#xD;
Since only one patient was enrolled prior to termination of the trial, no data summarization or analysis was carried out.</description>
        <time_frame>Data collected up to cut-off date 09 Sep 2016, Up to 02 months</time_frame>
        <population>Randomized set (RS): Comprising all patients who have a randomization date recorded in the electronic Case record form (eCRF).</population>
        <group_list>
          <group group_id="O1">
            <title>Nintedanib Plus Capecitabine</title>
            <description>Patients were to be orally administered tablets of Nintedanib and 1000 mg/m2 Capecitabine twice daily.&#xD;
Nintedanib: 21 day cycles; Capecitabine: first 14 days of each 21 day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS)</title>
          <description>PFS is defined as the time from randomization until objective tumor progression or death.&#xD;
Since only one patient was enrolled prior to termination of the trial, no data summarization or analysis was carried out.</description>
          <population>Randomized set (RS): Comprising all patients who have a randomization date recorded in the electronic Case record form (eCRF).</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Since only one patient was enrolled prior to termination of the trial, no data summarization or analysis was carried out.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>Overall survival is defined as the time from randomization until death from any cause.&#xD;
Since only one patient was enrolled prior to termination of the trial, no data summarization or analysis was carried out.</description>
        <time_frame>Data collected up to cut-off date 09 Sep 2016, Up to 02 months</time_frame>
        <population>RS</population>
        <group_list>
          <group group_id="O1">
            <title>Nintedanib Plus Capecitabine</title>
            <description>Patients were to be orally administered tablets of Nintedanib and 1000 mg/m2 Capecitabine twice daily.&#xD;
Nintedanib: 21 day cycles; Capecitabine: first 14 days of each 21 day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>Overall survival is defined as the time from randomization until death from any cause.&#xD;
Since only one patient was enrolled prior to termination of the trial, no data summarization or analysis was carried out.</description>
          <population>RS</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Since only one patient was enrolled prior to termination of the trial, no data summarization or analysis was carried out.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate (ORR)</title>
        <description>ORR is defined as complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.&#xD;
Since only one patient was enrolled prior to termination of the trial, no data summarization or analysis was carried out.</description>
        <time_frame>tumor response was to be assessed by imaging according to RECIST (version 1.1) every 6 weeks.</time_frame>
        <population>RS</population>
        <group_list>
          <group group_id="O1">
            <title>Nintedanib Plus Capecitabine</title>
            <description>Patients were to be orally administered tablets of Nintedanib and 1000 mg/m2 Capecitabine twice daily.&#xD;
Nintedanib: 21 day cycles; Capecitabine: first 14 days of each 21 day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (ORR)</title>
          <description>ORR is defined as complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.&#xD;
Since only one patient was enrolled prior to termination of the trial, no data summarization or analysis was carried out.</description>
          <population>RS</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Since only one patient was enrolled prior to termination of the trial, no data summarization or analysis was carried out.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Control (DC)</title>
        <description>Disease control is defined as CR or PR or Stable disease (SD) per RECIST version 1.1.&#xD;
Since only one patient was enrolled prior to termination of the trial, no data summarization or analysis was carried out.</description>
        <time_frame>Data collected up to cut-off date 09 Sep 2016, Up to 02 months</time_frame>
        <population>RS</population>
        <group_list>
          <group group_id="O1">
            <title>Nintedanib Plus Capecitabine</title>
            <description>Patients were to be orally administered tablets of Nintedanib and 1000 mg/m2 Capecitabine twice daily.&#xD;
Nintedanib: 21 day cycles; Capecitabine: first 14 days of each 21 day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Control (DC)</title>
          <description>Disease control is defined as CR or PR or Stable disease (SD) per RECIST version 1.1.&#xD;
Since only one patient was enrolled prior to termination of the trial, no data summarization or analysis was carried out.</description>
          <population>RS</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Since only one patient was enrolled prior to termination of the trial, no data summarization or analysis was carried out.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Grade 3 or Worse Adverse Events</title>
        <description>Percentage of patients with grade 3 or worse adverse events.</description>
        <time_frame>Data collected up to cut-off date 09 Sep 2016, Up to 02 months</time_frame>
        <population>RS</population>
        <group_list>
          <group group_id="O1">
            <title>Nintedanib Plus Capecitabine</title>
            <description>Patients were to be orally administered tablets of Nintedanib and 1000 mg/m2 Capecitabine twice daily.&#xD;
Nintedanib: 21 day cycles; Capecitabine: first 14 days of each 21 day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Grade 3 or Worse Adverse Events</title>
          <description>Percentage of patients with grade 3 or worse adverse events.</description>
          <population>RS</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first drug administration till end of trial; up to 3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Nintedanib Plus Capecitabine</title>
          <description>Patients were to be orally administered tablets of Nintedanib and 1000 mg/m2 Capecitabine twice daily.&#xD;
Nintedanib: 21 day cycles; Capecitabine: first 14 days of each 21 day cycle</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Trial was terminated prematurely because it was determined that nintedanib monotherapy demonstrated lack of efficacy in this indication in pivotal Phase III trial (LUME-Colon 1) that was ongoing at the time of the initiation of this trial.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Boehringer IIngelheim, Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

